{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T23:10:44Z","timestamp":1789859444498,"version":"4.0.1"},"reference-count":22,"publisher":"Royal College of Psychiatrists","issue":"6","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":5876,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Although serotonin reuptake inhibitors are effective in panic disorder, questions concerning whether doses associated with antidepressant efficacy are also effective for panic disorder remain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To assess the efficacy of the usual antidepressant dose of fluoxetine in treating full panic attacks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Patients with panic disorder were randomised to placebo or to fluoxetine initiated at 10 mg daily for I week and then increased to 20 mg daily. The trial lasted 12 weeks, but after 6 weeks patients who had failed to achieve a satisfactory response were eligible for dose escalation to a maximum of 60 mg of fluoxetine daily.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fluoxetine was associated with a statistically significantly greater proportion of panic-free patients compared with placebo after 6 weeks and at end-point.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Fluoxetine at a dose of 20 mg daily is safe and efficacious in reducing symptoms of panic disorder. Patients who fail to obtain a satisfactory response at 20 mg daily may benefit from further dose increases.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.179.6.514","type":"journal-article","created":{"date-parts":[[2002,8,29]],"date-time":"2002-08-29T21:36:18Z","timestamp":1030656978000},"page":"514-518","source":"Crossref","is-referenced-by-count":56,"title":["Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder"],"prefix":"10.1192","volume":"179","author":[{"given":"D.","family":"Michelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Allgulander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Dantendorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Maierhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Micev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. R.","family":"Paunovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Timotijevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Skoglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. C.","family":"Pemberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000160064_ref6","volume-title":"Structured Clinical Interview for DSM\u2013IV (SCID\u2013I): User's Guide and Interview, Research Version","author":"First","year":"1995"},{"key":"S0007125000160064_ref7","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1176\/ajp.147.4.532b","article-title":"Overcoming hypersensitivity to fluoxetine in a patient with panic disorder","volume":"147","author":"Giesecke","year":"1990","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000160064_ref1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"S0007125000160064_ref18","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.11.1571"},{"key":"S0007125000160064_ref9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"S0007125000160064_ref16","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-198708000-00005"},{"key":"S0007125000160064_ref14","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.9.1189"},{"key":"S0007125000160064_ref20","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200015060-00004"},{"key":"S0007125000160064_ref22","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.170.6.549"},{"key":"S0007125000160064_ref2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.1.36"},{"key":"S0007125000160064_ref8","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"S0007125000160064_ref11","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.173.1.54"},{"key":"S0007125000160064_ref12","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.11.1570"},{"key":"S0007125000160064_ref5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00004850-199300830-00010","article-title":"Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression","volume":"8","author":"Casacchia","year":"1993","journal-title":"International Clinical Psychopharmacology"},{"key":"S0007125000160064_ref13","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.167.3.374"},{"key":"S0007125000160064_ref21","volume-title":"Manual for the State\u2013Trait Anxiety Inventory","author":"Spielberger","year":"1983"},{"key":"S0007125000160064_ref3","first-page":"294","article-title":"Fluoxetine versus trazodone: efficacy and activating\u2013sedating effects","volume":"52","author":"Beasley","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000160064_ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.55.11.1010"},{"key":"S0007125000160064_ref19","volume-title":"The Anxiety Disease","author":"Sheehan","year":"1983"},{"key":"S0007125000160064_ref10","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199310000-00004"},{"key":"S0007125000160064_ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1993.01820130046008"},{"key":"S0007125000160064_ref17","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199004000-00007"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000160064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:45:48Z","timestamp":1639140348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000160064\/type\/journal_article"}},"subtitle":["Randomised, placebo-controlled trial"],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["S0007125000160064"],"URL":"https:\/\/doi.org\/10.1192\/bjp.179.6.514","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}